Agronomics Limited (GB:ANIC)
LSE:ANIC
Want to see GB:ANIC full AI Analyst Report?
Top Page
Agronomics
(LSE:ANIC)
Select Model
Select Model
Rating:44Neutral
Price Target:
7.00 p
▲(9.37% Upside)
Action:Reiterated
Date:01/04/26
The score is weighed down primarily by weak financial performance (recent losses and persistently negative cash flow), with technicals also bearish (price below key moving averages and negative MACD). Valuation is additionally constrained by a negative P/E driven by losses and no dividend data to offset risk; the main positive is the debt-free balance sheet, though equity has been eroding.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving Agronomics durability through long development cycles. This provides optionality to fund follow-on investments or survive cash burn without immediate leveraged pressure, supporting long-term portfolio strategy.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow erodes financial flexibility and forces dependence on capital raises or asset sales to fund operations and follow-ons. Over months this increases dilution risk, constrains ability to support portfolio companies through long commercialization timelines, and raises funding execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving Agronomics durability through long development cycles. This provides optionality to fund follow-on investments or survive cash burn without immediate leveraged pressure, supporting long-term portfolio strategy.
Read all positive factors
Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£73.67M
Dividend YieldN/A
Average Volume (3M)2.60M
Price to Earnings (P/E)1.6
Beta (1Y)1.49
Revenue GrowthN/A
EPS Growth5.88%
CountryUK
EmployeesN/A
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,083,381,100
10 Day Avg. Volume2,299,252
30 Day Avg. Volume2,599,051
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)-5.97
P/FCF Ratio-63.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Agronomics Business Overview & Revenue Model
Company Description
Agronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on...
How the Company Makes Money
Agronomics primarily makes money through investment returns from its portfolio rather than through operating revenue from selling products or services. Its main potential earnings drivers are: (1) Realized gains on exits: selling equity stakes in ...
Agronomics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -11.92M | -11.92M | -8.34M | 29.70M | 440.32K | 10.67M |
| Gross Profit | 0.00 | 0.00 | -8.34M | 29.70M | 440.32K | 10.67M |
| EBITDA | -10.05M | -26.47M | 0.00 | 0.00 | 1.50M | 0.00 |
| Net Income | -16.18M | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
Balance Sheet | ||||||
| Total Assets | 140.21M | 124.67M | 157.44M | 170.20M | 146.40M | 101.65M |
| Cash, Cash Equivalents and Short-Term Investments | 2.15M | 124.62M | 12.24M | 169.87M | 146.30M | 101.21M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 234.67K | 147.60K | 166.17K | 1.95M | 2.49M | 1.62M |
| Stockholders Equity | 139.97M | 124.52M | 157.27M | 168.26M | 143.91M | 100.03M |
Cash Flow | ||||||
| Free Cash Flow | -1.24M | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Operating Cash Flow | -1.24M | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Investing Cash Flow | 2.28M | 1.59M | 892.00K | 10.02M | -20.02M | -11.21M |
| Financing Cash Flow | 0.00 | 1.71K | 1.68K | 1.01M | 31.25M | 71.82M |
Agronomics Technical Analysis
Positive
6.40
Price Trends
6.68
Positive
6.41
Positive
6.75
Positive
Market Momentum
0.02
Negative
55.70
Neutral
53.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANIC, the sentiment is Positive. The current price of 6.4 is below the 20-day moving average (MA) of 6.68, below the 50-day MA of 6.68, and below the 200-day MA of 6.75, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.70 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ANIC.
Agronomics Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | £122.88M | 21.20 | 1.79% | 3.29% | -9.37% | ― | |
64 Neutral | £125.96M | 6.86 | 17.51% | 17.93% | -22.86% | -56.06% | |
63 Neutral | £973.11M | 2.30 | 8.81% | ― | 11.00% | ― | |
61 Neutral | £572.46M | 1.18 | 7.16% | ― | -35.12% | ― | |
44 Neutral | £73.67M | 1.56 | -12.24% | ― | ― | 5.88% | |
42 Neutral | £13.00M | -754.01 | -16.69% | ― | 16.98% | 99.21% |
* Financial Sector Average
GB:ANIC
Agronomics
6.75
0.10
1.50%
GB:GROW
Molten Ventures
587.50
286.50
95.18%
GB:IPX
Impax Asset Management
99.60
-67.00
-40.22%
GB:IPO
IP Group plc
65.70
22.55
52.26%
GB:MERC
Mercia Asset Management
29.00
1.36
4.92%
GB:EMVC
NetScientific
45.00
4.50
11.11%
Agronomics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Agronomics Portfolio Firm Tropic Secures $105m to Scale Gene‑Edited Tropical Crops
Positive
Mar 19, 2026
Agronomics has highlighted a major milestone at portfolio company Tropic Biosciences, which has raised $105 million in an oversubscribed Series C round to scale global production of its gene-edited banana and rice varieties and advance a broader p...
Other
Agronomics Chair Jim Mellon Lifts Stake to Nearly 16% With Fresh Share Purchases
Positive
Mar 12, 2026
Agronomics Limited has disclosed that its Executive Chair, Jim Mellon, has purchased a total of 3,308,995 additional ordinary shares in a series of market transactions between 6 and 12 March 2026. The shares were acquired at prices ranging from 6....
Business Operations and Strategy
Agronomics Chair Jim Mellon Increases Stake to Over 15%
Positive
Mar 4, 2026
Agronomics Limited has disclosed that its executive chair, Jim Mellon, along with his indirectly wholly owned vehicle Galloway Limited, has acquired a combined 575,785 ordinary shares in the company at a price of 6.8 pence per share over several t...
Business Operations and Strategy
Agronomics Chair Jim Mellon Increases Stake with 990,000‑Share Purchase
Positive
Feb 25, 2026
Agronomics Limited has disclosed that Galloway Limited, an entity indirectly wholly owned by Executive Chair Jim Mellon, has acquired a total of 990,000 additional ordinary shares in the company over three consecutive trading days. The purchases, ...
Business Operations and StrategyRegulatory Filings and Compliance
Agronomics Chair Jim Mellon Increases Stake to Over 15%
Positive
Feb 20, 2026
Agronomics Limited has disclosed that Galloway Limited, an entity indirectly wholly owned by Executive Chair Jim Mellon, has acquired more than 1.28 million ordinary shares in the company over three consecutive trading days at around 6 pence per s...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Agronomics Swings to Profit as Clean Food Portfolio Gains Value
Positive
Feb 17, 2026
Agronomics reported a sharp turnaround to a net profit of £10 million for the six months to 31 December 2025, driven by £10.7 million of net investment gains and only modest operating costs. Net asset value per share rose 11.7% to 13.78 ...
Business Operations and StrategyShareholder Meetings
Agronomics Wins Full Shareholder Backing at Annual General Meeting
Positive
Feb 13, 2026
Agronomics Limited announced that all resolutions proposed at its Annual General Meeting held on 13 February 2026 were duly passed. The approval of all AGM resolutions provides the company with shareholder backing for its current strategy and gove...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Agronomics Boosts Stake in Precision Fermentation Firm All G with AU$3 Million Note Investment
Positive
Jan 15, 2026
Agronomics has invested a further AU$3 million in Australian biotech All G, which uses precision fermentation to produce human and bovine milk proteins, notably animal‑free lactoferrin for applications in infant and clinical nutrition, funct...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Agronomics Takes Heavy Write-Downs but Portfolio Wins Key Regulatory and Commercial Milestones
Negative
Dec 30, 2025
Agronomics reported a sharp decline in performance for the year to 30 June 2025, with net asset value per share falling 20% to 12.34 pence and a swing to a £32.7 million net operating loss, driven largely by £25.1 million of net investme...
Business Operations and StrategyPrivate Placements and Financing
Agronomics boosts BlueNalu stake with US$6.6m mix of equity and convertible notes
Positive
Dec 30, 2025
Agronomics has deepened its exposure to cultivated seafood pioneer BlueNalu with a US$6 million equity subscription in new preferred shares and a further US$600,000 investment in BlueNalu’s 2025 convertible promissory note round, taking its ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.